Dirk Ramaekers

Dirk Ramaekers

Auto-generated profile, based on publicly available information

Dirk Ramaekers

Leuvens Institute for Healthcare Policy (LIHP) Katholieke Universiteit Leuven (KUL) Leuven Belgium

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2009 in International Archives of Occupational and Environmental Health
Verified
Journal Article
Closed access
PDF file
AHAnnemie Heselmans
Annemie Heselmans
PDPeter Donceel
Peter Donceel
BABert Aertgeerts
Bert Aertgeerts
SVStijn Van de Velde
Stijn Van de Velde
DRDirk Ramaekers
Dirk Ramaekers

25 February 2022 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
PDF file
ESE. Van Den Steen
E. Van Den Steen
DRD. Ramaekers
D. Ramaekers
MHM. Horlait
M. Horlait
JGJ. Gutermuth
J. Gutermuth
Background: Patient involvement and high‐quality patient‐provider interactions are critical factors for quality of care in chronic inflammatory skin diseases. Also, assessing the patient's perspective contributes to optimizing care delivery and patient's experience. Until today, no user‐friendly tools to measure patient experiences exist within immunodermatology.Objectives: The aim of this study was to identify the relevant items for patient's experience in immunodermatology and develop a concise questionnaire to assess patient's experience in routine clinical care.Methods: Potential relevant items for measuring patient's perspective of immunodermatology care were identified by a literature search. From this longlist, a shortlist from patient's perspective was distilled by semi‐structured interviews with a diverse patient group. This list was reduced to final items using a modified Delphi method in a multi‐stakeholder focus group. For each item, one question was formulated to generate the Patient‐Reported Experience Measure (PREM) questionnaire. A first internal validation was achieved by an email round.Results: Forty longlist items were categorized into five domains (access to care, patient centeredness, access to information, care process and satisfaction). During interview rounds, 19 shortlist items were selected if mentioned by ≥40% of interviewees. Via the focus group, the most important items were chosen by participant consensus. For each item, a question was formulated. The final PREM covers 11 items (plus 2 in case of a first consult). The first internal validation showed that the tool is clear, understandable and has an ideal length.Conclusion: This short user‐friendly PREM can be used in scientific and routine settings to improve care for patients who suffer from chronic inflammatory skin diseases.

24 January 2008 in International Journal of Technology Assessment in Health Care
Verified
Journal Article
Closed access
PDF file
ICIrina Cleemput
Irina Cleemput
CCCécile Camberlin
Cécile Camberlin
ABAnn Van Den Bruel
Ann Van Den Bruel
DRDirk Ramaekers
Dirk Ramaekers
Objectives: The aim of this study was to develop a methodology for calculating the need for positron emission tomography (PET) scanners in a country and illustrate this methodology for Belgium. Methods: First, levels of evidence were assigned to PET in different indications according to a standard hierarchical classification system. The level reached depends on whether there is evidence on diagnostic accuracy, impact on diagnostic thinking, therapeutic impact, impact on patient outcomes, or cost-effectiveness. Second, the number of patients eligible for PET for each indication was derived from a registry of PET. Third, the number of PET scanners needed in Belgium was estimated for different baseline hypotheses about maximum annual capacity of a scanner and the minimally required level of evidence. Results: The number of PET scanners needed crucially depends on the level of evidence considered acceptable for the implementation of PET: the higher the level of evidence required, the lower the number of PET scanners needed. Belgium needs at least three and at most ten PET scanners. This contrasts with the thirteen currently approved. Conclusions: Scientific evidence and information on the eligible population for a specific procedure are crucial elements for policy makers who wish to make evidence-based decisions about programming and planning of heavy medical equipment.